Pfizer Malaysia
Pfizer Malaysia Sdn Bhd, the Malaysian subsidiary of Pfizer Inc., develops and commercializes innovative prescription medicines, vaccines, and patient assistance programs across oncology, vaccines, internal medicine, and rare disease for healthcare providers, government, and patients in Malaysia.
- Company typePrivate
- Founded1978
- HeadquartersKuala Lumpur, Malaysia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pfizer Malaysia does
Pfizer Malaysia Sdn Bhd is the Malaysian operating subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Incorporated in Malaysia in 1978 and headquartered in Bangsar South, Kuala Lumpur with a lean 46-employee team, the company develops, markets, and distributes innovative prescription medicines, vaccines, and consumer health products across therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease. The portfolio spans established hospital products such as the Zavicefta antibiotic (ceftazidime/avibactam), the Pfizer-BioNTech COVID-19 vaccine supplied under the National Immunization Program via JKJAV, pneumococcal vaccines for adult and pilgrimage populations, and an industry-leading oncology portfolio of 22 approved cancer medicines across 30+ indications. The company also operates patient assistance programmes such as ALKare PLUS for ALK-positive NSCLC patients, digital therapeutics platforms in partnership with DoctorOnCall, and the Care-A-Van mobile community health screening programme that has reached over 156,000 lives across 800 locations over 22 years.
Pfizer Malaysia's business model is built on enterprise field sales to hospitals, clinics, and pharmacies, complemented by direct government vaccine supply contracts, partnerships with telehealth platforms (DoctorOnCall) and consumer financing partners (UOB Malaysia), and a layer of patient assistance and disease awareness programs delivered jointly with Malaysian patient advocacy organizations (LCNM, NCSM, BCWA, MTS, MRCS). Revenue mechanics are one-time license-style sales of prescription pharmaceuticals and vaccines, with pricing not publicly disclosed and patient cost addressed through programs such as ALKare PLUS and the ASK4VACCINE 12-month interest-free instalment plan. Customer segments span healthcare providers, government (JKJAV / Ministry of Health for COVID-19 vaccination), and patient populations including ALK-positive NSCLC patients, metastatic breast cancer patients and caregivers, Hajj and Umrah pilgrims, older adults aged 50+, and B40 underserved communities.
The company is led by Country Manager Luksanawan Thangpaibool (also covering Brunei) and Country Medical Director Dr. Jerusha Naidoo. It draws on the parent Pfizer Inc.'s global R&D infrastructure (25,000 clinical researchers) and benefits from Pfizer's 170+ year brand heritage and 2023 Fortune recognitions including World's Most Admired Companies All-Stars, World's Best Companies, Best Employers for New Grads, and Equality 100 Award. Geographic scope is single-country domestic, with distribution routed through direct sales, government health programs, and channel partnerships.
Pfizer Malaysia firmographics
Firmographics- Name
- Pfizer Malaysia
- Legal name
- Pfizer Malaysia Sdn Bhd
- Website
- https://pfizer.com.my
- Company type
- Private
- Founded year
- 1978
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pfizer Malaysia Sdn Bhd, the Malaysian subsidiary of Pfizer Inc., develops and commercializes innovative prescription medicines, vaccines, and patient assistance programs across oncology, vaccines, internal medicine, and rare disease for healthcare providers, government, and patients in Malaysia.
- Ownership category
- akta.pro rank
Pfizer Malaysia industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
- akta.pro secondary industries
- Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccines & Public Health Product Distribution (CRAOAHAI)
Keywords
Where Pfizer Malaysia is headquartered
LocationHeadquarters
- HQ city
- Kuala Lumpur
- HQ country
- Malaysia
- HQ region
- Asia
Offices1 record
Markets served
Pfizer Malaysia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Medicines: Pfizer develops and sells innovative prescription medicines across therapeutic areas including Oncology, Inflammation & Immunology, Internal Medicine, and Rare Disease. Revenue generated through direct sales to healthcare providers and pharmacies.
- Vaccines: Pfizer manufactures and distributes vaccines including pneumococcal vaccines and COVID-19 vaccine. Revenue generated through government contracts and healthcare provider sales.
- Consumer Health Care Products: Pfizer offers consumer healthcare products as part of its global portfolio alongside prescription medicines and vaccines.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Pfizer Malaysia product offering
Product offeringCore offering
Pfizer Malaysia develops, markets, and distributes innovative prescription medicines and vaccines to healthcare providers, pharmacies, and government health programs in Malaysia. Its portfolio spans Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, and Vaccines, including specific products such as the Zavicefta antibiotic for serious Gram-negative bacterial infections and COVID-19 and pneumococcal vaccines supplied through the National Immunization Program.
Product overview
Pfizer Malaysia operates as a biopharmaceutical company within the Pfizer global network, offering a portfolio of innovative medicines, vaccines, and digital health solutions. The product portfolio includes pharmaceutical products (antibiotics such as Zavicefta), patient assistance programmes (ALKare PLUS for lung cancer patients), and mobile/community health services (Care-A-Van reaching 156,000+ lives). Pfizer Malaysia also provides digital health platforms developed in partnership with DoctorOnCall, patient education resources including the Me & mBC guide for metastatic breast cancer and lung cancer patient handbook, and disease prevention platforms like PreventPneumonia.com.my. The company focuses on therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease, serving healthcare professionals, patients, and the Malaysian community through integrated digital and physical health programmes.
Differentiator
Problem solved
Functional benefit
Products and services
- Zavicefta (ceftazidime/avibactam) Novel combination antibiotic combining ceftazidime (third-generation antipseudomonal cephalosporin) with avibactam (beta-lactamase inhibitor) for treating serious Gram-negative bacterial infections in hospitalised adults aged 18 years and above. Indicated for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), Hospital-Acquired Pneumonia (HAP), and Ventilator Associated Pneumonia (VAP).
- ALKare PLUS Patient Assistance Programme Patient assistance programme that helps ALK-positive advanced non-small cell lung cancer (NSCLC) patients in Malaysia access and continue innovative targeted therapies through financial support, treatment continuity planning, and education services.
- Care-A-Van Mobile Health Screening Programme Mobile community health screening and outreach programme delivering healthcare awareness and basic health services to underserved and underprivileged communities in Malaysia. Has reached more than 156,000 lives across 800 locations over 22 years and covers breast health, mental health, and disease prevention education.
- Pfizer-BioNTech COVID-19 Vaccine (Malaysian supply) Pfizer-BioNTech COVID-19 vaccine supplied to Malaysia through a partnership with JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply) for deployment under the National Covid-19 Immunization Program, administered via government health channels and partner providers.
- ASK4VACCINE Pneumococcal Vaccination Programme Pneumococcal vaccination access programme that enables Malaysian parents to obtain paediatric pneumococcal vaccination with a 12-month interest-free instalment payment plan when paying via UOB Malaysia credit cards, addressing affordability barriers to childhood immunisation.
- Pneumococcal Vaccines (Prevenar family) for Hajj/Umrah Pilgrims and Older Adults
Quantifiable outcome
- 156,000+ lives touched through Care-A-Van mobile health screening program across 800 locations
- +1 more outcomes
Companies that use Pfizer Malaysia
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles3 records
Pfizer Malaysia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pfizer Malaysia partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered minor and core.
- University of Malaya (UM)minorPartnership in University For Society (U4S) Central Zone program. UM focuses on Building Resilience for Society with mental health webinars and Construction Skills Training Module for youth community.
- Universiti Teknologi MARA (UiTM)minorPartnership in U4S Central Zone program. UiTM runs Financial Independence Strategy for Community Entrepreneur (FISCENT) project with business networking and workshop programs.
- International Islamic University Malaysia (IIUM)minorPartnership in U4S Central Zone program. IIUM runs Creative Youth (CR8V Youth) project and Integrated and Sustainable Agriculture Farming (InSAF) project.
- BUMITRA MalaysiacoreMOU to drive pneumococcal disease prevention awareness among Hajj and Umrah pilgrims. Campaign uses BUMITRA Malaysia Facebook page to provide information about pneumococcal pneumonia through comics, posters, infographics, and animated videos.
- Lung Cancer Network Malaysia (LCNM)corePartnership with LCNM and NCSM to launch Malaysia's first digital lung cancer patient handbook. The #KeepBreathing campaign improves public understanding of lung cancer and addresses misconceptions about the disease.
- National Cancer Society Malaysia (NCSM)corePartnership with NCSM to develop Malaysia's first digital lung cancer patient handbook to improve health literacy and facilitate better communication between patients and healthcare providers.
- Breast Cancer Welfare Association Malaysia (BCWA)coreSupport for #UNPAUSE 2021 campaign celebrating and recognizing cancer caregivers. Launch of Me & mBC digital guide and audiobook to improve metastatic breast cancer literacy and patient-caregiver communication.
- BookDoccorePartnership for 'Mental Health for All' digital campaign addressing mental health concerns in Malaysia. Provides resources on mental health conditions, self-assessment quizzes, and connects users to mental health specialists via tele-consult.
- JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply)corePartnership with JKJAV under Ministry of Health and Ministry of Science, Technology and Innovation for supply and implementation of Pfizer-BioNTech COVID-19 vaccine in National Immunization Program.
- UOB MalaysiacoreMalaysia's first tripartite collaboration between DoctorOnCall, Pfizer, and UOB Malaysia. The ASK4VACCINE program enables Malaysian parents to provide pneumococcal vaccination for children via a 12-month interest-free instalment payment plan for UOB Malaysia credit card holders.
- Malaysian Thoracic Society (MTS)coreLaunch of 'You Are Our Best Shot' campaign to normalize adult vaccination and improve health literacy for higher vaccination uptake among older adults. Includes digital resource hub at preventpneumonia.com.my.
- Malaysian Red Crescent Society (MRCS)coreMOU to provide psychosocial support for Malaysians dealing with COVID-19 pandemic challenges. Programs include RedCrescent4u Careline, Care-A-Van x MyVac program for health screening in rural areas, and health webinars. Care-A-Van has touched 156,000+ lives across 800 locations.
- DoctorOnCallcorePfizer collaborated with DoctorOnCall to launch a digital therapeutics platform focusing on three key therapeutic areas: smoking cessation, vaccination, and heart health. The platform includes health centers with educational content, engagement tools, and free doctor consultations.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Pfizer Malaysia competitors and assessment
Company assessmentDirect peers
- Sanofi Malaysia: Sanofi Malaysia is the Malaysian subsidiary of Sanofi, a peer multinational pharmaceutical company. Both Pfizer Malaysia and Sanofi Malaysia operate in vaccines, specialty care, and consumer health with similar hospital and pharmacy go-to-market models.
- Johnson & Johnson Malaysia: Johnson & Johnson Malaysia is the Malaysian subsidiary of J&J, operating across pharmaceuticals, medical devices, and consumer health. It is a close peer to Pfizer Malaysia given overlapping therapeutic areas and similar commercial model targeting hospitals and specialists.
- AstraZeneca Malaysia: AstraZeneca Malaysia is the Malaysian subsidiary of AstraZeneca, a peer global biopharmaceutical company. Both compete in oncology, respiratory, and vaccine categories through hospital and government channels in Malaysia.
- Novartis Malaysia: Novartis Malaysia is the Malaysian arm of Novartis, another large multinational pharma with presence in oncology, cardiovascular, and immunology. It competes directly with Pfizer Malaysia across specialty therapeutics and hospital sales channels in Malaysia.
- Merck Sharp & Dohme (MSD) Malaysia: MSD Malaysia is the Malaysian subsidiary of Merck & Co., a direct peer in oncology, vaccines, and specialty therapeutics. Both target similar hospital, government, and pharmacy customers with comparable global pharma playbooks.
- Boehringer Ingelheim Malaysia: Boehringer Ingelheim Malaysia is the Malaysian arm of Boehringer Ingelheim, a multinational pharma peer focused on respiratory, cardiometabolic, and specialty therapeutics. It competes with Pfizer Malaysia for hospital channel share in similar specialty care segments.
- Bayer Malaysia: Bayer Malaysia is the Malaysian subsidiary of Bayer, a comparable multinational pharma with presence in pharmaceuticals, consumer health, and animal health. It is a relevant peer given overlap in cardiovascular and women's health therapeutic areas.
- Eli Lilly Malaysia: Eli Lilly Malaysia is the Malaysian subsidiary of Eli Lilly, a multinational pharma peer with growing emphasis on oncology, diabetes, and immunology. Both compete for the same specialty prescriber audience in Malaysia's hospital channel.
- GSK Malaysia: GSK Malaysia is the Malaysian subsidiary of GSK, a direct peer with a comparable vaccines and specialty pharmaceuticals portfolio. Both compete head-to-head in adult and travel vaccination markets and consumer health adjacencies in Malaysia.
- Roche Malaysia: Roche Malaysia is the Malaysian subsidiary of Roche Holding, a peer multinational pharmaceutical company. Both are wholly-owned subsidiaries of global pharma majors operating in Malaysia with oncology, specialty therapeutics, and biologics portfolios, targeting the same hospital and government channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Pfizer Malaysia social profiles
Digital presencePfizer Malaysia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pfizer Malaysia leadership team
Management profileNumber of profiles
Profiles2 records
Pfizer Malaysia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pfizer Malaysia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pfizer Malaysia
What does Pfizer Malaysia do?
Pfizer Malaysia develops, markets, and distributes innovative prescription medicines and vaccines to healthcare providers, pharmacies, and government health programs in Malaysia. Its portfolio spans Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, and Vaccines, including specific products such as the Zavicefta antibiotic for serious Gram-negative bacterial infections and COVID-19 and pneumococcal vaccines supplied through the National Immunization Program.
Is Pfizer Malaysia a public or private company?
Pfizer Malaysia is a private company. It is classified as corporate owned and is currently operating.
When was Pfizer Malaysia founded?
Pfizer Malaysia was founded in 1978. It employs 11 to 50 people.
Where is Pfizer Malaysia based?
Pfizer Malaysia is headquartered in Kuala Lumpur, Malaysia, in the Asia region.
How does Pfizer Malaysia make money?
Three revenue lines are on record. Pharmaceutical Medicines are the primary driver. The others are vaccines and consumer Health Care Products.
Who are Pfizer Malaysia's main competitors?
Direct peers on record are Sanofi Malaysia, Johnson & Johnson Malaysia, AstraZeneca Malaysia, Novartis Malaysia, Merck Sharp & Dohme (MSD) Malaysia, Boehringer Ingelheim Malaysia, Bayer Malaysia, Eli Lilly Malaysia, GSK Malaysia and Roche Malaysia.
Does Pfizer Malaysia have an API?
No public API is recorded for Pfizer Malaysia.
What industry is Pfizer Malaysia in?
Pfizer Malaysia's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAJAG, Vaccines & Cold-Chain Pharmaceutical Distributors. Its NAICS code is 325414 and its SIC code is 2836.